Observational studyInvestigative and clinical urology2026

Intravesical gemcitabine versus Bacillus Calmette-Guérin (BCG) for intermediate-/high-risk non-muscle-invasive bladder cancer during the BCG shortage: Safety, efficacy, and health-economic context.

Tiago Mestriner Costa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.